Hussman Strategic Advisors Inc. Acquires Shares of 31,500 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Hussman Strategic Advisors Inc. acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 31,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,741,000. Hussman Strategic Advisors Inc. owned approximately 0.15% of ANI Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the company. Thrivent Financial for Lutherans boosted its position in ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after acquiring an additional 299 shares in the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 3.9% during the third quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $477,000 after purchasing an additional 300 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of ANI Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after purchasing an additional 310 shares during the last quarter. New York State Teachers Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after purchasing an additional 412 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,781 shares of company stock valued at $2,465,372. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $59.99 on Thursday. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.81. The firm has a market cap of $1.26 billion, a P/E ratio of -109.07 and a beta of 0.74. The company has a 50 day moving average of $56.99 and a 200 day moving average of $58.23. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.